PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its stake in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) by 4.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,200 shares of the company’s stock after selling 8,405 shares during the period. Geode Capital Management LLC owned about 2.19% of PharmaCyte Biotech worth $321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

PharmaCyte Biotech Stock Performance

PMCB opened at $1.52 on Tuesday. PharmaCyte Biotech, Inc. has a one year low of $1.39 and a one year high of $2.58. The company has a market cap of $10.59 million, a P/E ratio of 2.87 and a beta of -0.22. The business’s 50-day simple moving average is $1.68 and its 200-day simple moving average is $1.79.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings data on Friday, December 13th. The company reported ($0.29) EPS for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.